SMMT

Summit Therapeutics (SMMT)

About Summit Therapeutics (SMMT)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Details

Daily high
$20.85
Daily low
$20.07
Price at open
$20.79
52 Week High
$33.89
52 Week Low
$2.10
Market cap
14.8B
Dividend yield
0.00%
Volume
1.8M
Avg. volume
2.9M
P/E ratio
-65.44

Summit Therapeutics News

Details

Daily high
$20.85
Daily low
$20.07
Price at open
$20.79
52 Week High
$33.89
52 Week Low
$2.10
Market cap
14.8B
Dividend yield
0.00%
Volume
1.8M
Avg. volume
2.9M
P/E ratio
-65.44